John McHutchison (Gilead Sciences Inc. (Nasdaq: GILD))

McHutchison, John (Gilead 201809 CSO)

	Organisation	Gilead Sciences Inc. (Nasdaq: GILD)
	Group	Gilead Sciences (Group)
	Product	pharmaceutical
	Product 2	drug development
	Source	Galapagos N.V.. (9/11/18). "Press Release: Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis". Foster City, CA & Mechelen.

Record changed: 2019-07-23

Picture [iito] Plain Stupid Simple 650x80px

More documents for John McHutchison

[1] Gilead Sciences, Inc.. (7/19/19). "Press Release: Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis". Foster City, CA....
[2] Galapagos N.V.. (5/29/19). "Press Release: Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)". Foster City, CA & Mechelen....
[3] Gilead Sciences, Inc.. (4/12/19). "Press Release: Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH". Foster City & Bagsvaerd....
[4] Aelix Therapeutics S.L.. (10/18/18). "Press Release: Aelix Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure"....
[5] Galapagos N.V.. (9/11/18). "Press Release: Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis". Foster City, CA & Mechelen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]